Literature DB >> 31436814

Incidence of Hospitalizations and Emergency Department Visits for Herpes Zoster in Immunocompromised and Immunocompetent Adults in Ontario, Canada, 2002-2016.

Sarah A Buchan1,2,3, Nick Daneman1,2,4,5,6,7, Jun Wang1,2, Gary Garber1,6,8,9, Anne E Wormsbecker10,11, Sarah E Wilson1,2,3, Shelley L Deeks1,3.   

Abstract

BACKGROUND: Immunocompromised adults are at .increased risk of herpes zoster (HZ) infection and related complications. We aimed to assess the incidence of hospital-attended HZ (ie, seen in hospital or emergency department) in immunocompromised populations and compare it to immunocompetent populations.
METHODS: We calculated incidence rates (IRs) of hospital-attended HZ in Ontario, Canada, between 1 April 2002 and 31 August 2016 in adults ≥18 years of age categorized as immunocompromised or immunocompetent. We repeated these analyses by type of immunocompromising condition and provided incidence rate ratios (IRRs) comparing to immunocompetent adults. We also calculated IRs and IRRs of HZ complications by immunocompromised status.
RESULTS: There were 135 206 incident cases of hospital-attended HZ during the study period. Immunocompromised adults accounted for 13% of these cases despite representing 3% of the population. The risk of hospital-attended HZ was higher for immunocompromised adults compared with immunocompetent adults (IRR, 2.9 [95% confidence interval {CI}, 2.9-3.0]) and ranged across type of immunocompromising conditions, from 2.6 (95% CI, 2.6-2.7) in those with a solid tumor malignancy to 12.3 (95% CI, 11.3-13.2) in those who had undergone hematopoietic stem cell transplant. The risk of any HZ complication was higher in immunocompromised adults (IRR, 3.6 [95% CI, 3.5-3.7]) and highest for disseminated zoster (IRR, 32.8 [95% CI, 27.8-38.6]).
CONCLUSIONS: The risk of hospital-attended HZ and related complications was higher in immunocompromised populations compared with immunocompetent populations. Our findings underscore the high-risk nature of this population and the potential benefits that may be realized through HZ vaccination. Her Majesty the Queen in Right of Canada, as represented by the Public Health Ontario, 2019.

Entities:  

Keywords:  administrative data; complications; herpes zoster; immunocompromising conditions; incidence

Year:  2020        PMID: 31436814     DOI: 10.1093/cid/ciz769

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient.

Authors:  Hiroki Kobayashi; Yusuke Yoshida; Tomoki Komoshita; Harumichi Suma; Yohei Hosokawa; Yoshikazu Hirose; Tomohiro Sugimoto; Sho Mokuda; Shintaro Hirata; Eiji Sugiyama
Journal:  Intern Med       Date:  2021-11-13       Impact factor: 1.282

2.  Herpes zoster in older adults in Ontario, 2002-2016: Investigating incidence and exploring equity.

Authors:  Sarah A Buchan; Nick Daneman; Jun Wang; Sarah E Wilson; Gary Garber; Anne E Wormsbecker; Tony Antoniou; Shelley L Deeks
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

3.  Increased Incidence of Giant Cell Arteritis After Introduction of a Live Varicella Zoster Virus Vaccine.

Authors:  William A Agger; Jake A Deviley; Andrew J Borgert; Cary M Rasmussen
Journal:  Open Forum Infect Dis       Date:  2020-12-30       Impact factor: 3.835

4.  Seropositivity, Risks, and Morbidity From Varicella-Zoster Virus Infections in an Adult PWH Cohort From 2000-2020.

Authors:  Jason Zou; Hartmut B Krentz; Raynell Lang; Brenda Beckthold; Kevin Fonseca; M John Gill
Journal:  Open Forum Infect Dis       Date:  2022-08-09       Impact factor: 4.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.